SCHEMBL5736819

SCHEMBL5736819

CC(C)[Sb](c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.36
TAAR1 Q96RJ0 6/20 0.33
LMNA P02545 3/20 0.33
SLC6A2 P23975 2/20 0.33
TSHR P16473 2/20 0.33
ALOX12 P18054 2/20 0.33
MAOA P21397 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ACHE P22303 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CYP2A6 P11509 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
ADRA2A P08913 1/20 0.32
ADRA2C P18825 1/20 0.32
CYP2D6 P10635 1/20 0.32
HIF1A Q16665 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL677787 0.76 TAAR1 (0.39) TAAR1LMNATSHRADRA2AADRA2C
SCHEMBL677789 0.71 SIGMAR1 (0.50) TAAR1SLC6A2MAOASLC6A4SLC6A3
SCHEMBL9312918 0.65 TSHR (0.39) TDP1LMNATSHRALOX12ACHE
SCHEMBL3888161 0.65
SCHEMBL169051 0.63 ALDH1A1 (0.40) TDP1LMNASLC6A2TSHRALOX12
SCHEMBL677170 0.63 ALDH1A1 (0.40) TDP1LMNASLC6A2TSHRALOX12
SCHEMBL13391696 0.61 HIF1A (0.41) TDP1TAAR1LMNASLC6A2TSHR
SCHEMBL10825574 0.61
Iodide SCHEMBL1794148 0.60 ALDH1A1 (0.38) TDP1LMNASLC6A2TSHRALOX12
Water SCHEMBL11743637 0.60 ALDH1A1 (0.38) TDP1LMNASLC6A2TSHRALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680218-A2 SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS Promerus, LLC (US) 2006-07-19 EP claimed
WO-2005042147-A2 SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS PROMERUS, LLC (US) 2005-05-12 WO claimed
EP-1680218-A2 SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS Promerus, LLC (US) 2006-07-19 EP disclosed
US-20050187398-A1 Single component cationic palladium proinitiators for the latent polymerization of cycloolefins PROMERUS, LLC 2005-08-25 US disclosed
WO-2005042147-A2 SINGLE COMPONENT CATIONIC PALLADIUM PROINITIATORS FOR THE LATENT POLYMERIZATION OF CYCLOOLEFINS PROMERUS, LLC (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187398-A1 Single component cationic palladium proinitiators for the latent polymerization of cycloolefins LRRK2, LBR, SNCA TDP1 3233/4885TAAR1 787/4885LMNA 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.